243 related articles for article (PubMed ID: 36944737)
1. Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models.
Gherardini L; Vetri Buratti V; Maturi M; Inzalaco G; Locatelli E; Sambri L; Gargiulo S; Barone V; Bonente D; Bertelli E; Tortorella S; Franci L; Fioravanti A; Comes Franchini M; Chiariello M
Sci Rep; 2023 Mar; 13(1):4630. PubMed ID: 36944737
[TBL] [Abstract][Full Text] [Related]
2. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
[TBL] [Abstract][Full Text] [Related]
3. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.
Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH
ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735
[TBL] [Abstract][Full Text] [Related]
4. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
6. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
7. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
8. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
Zhao W; Yun K
Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776
[TBL] [Abstract][Full Text] [Related]
9. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.
Jatyan R; Sahel DK; Singh P; Sakhuja R; Mittal A; Chitkara D
J Control Release; 2023 Jul; 359():161-174. PubMed ID: 37182806
[TBL] [Abstract][Full Text] [Related]
11. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
12. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV
Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821
[TBL] [Abstract][Full Text] [Related]
13. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
Yu J; Gao G; Wei X; Wang Y
BMC Cancer; 2022 Jul; 22(1):786. PubMed ID: 35850753
[TBL] [Abstract][Full Text] [Related]
14. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study.
Yu Y; Wang A; Wang S; Sun Y; Chu L; Zhou L; Yang X; Liu X; Sha C; Sun K; Xu L
Mol Pharm; 2022 Apr; 19(4):1219-1229. PubMed ID: 35262365
[TBL] [Abstract][Full Text] [Related]
17. PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
Yang E; Wang L; Jin W; Liu X; Wang Q; Wu Y; Tan Y; Wang Y; Cui X; Zhao J; Tong F; Hong B; Xiao M; Liu X; Fang C; Kang C
Theranostics; 2022; 12(9):4330-4347. PubMed ID: 35673568
[No Abstract] [Full Text] [Related]
18. Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.
Zou Y; Wang Y; Xu S; Liu Y; Yin J; Lovejoy DB; Zheng M; Liang XJ; Park JB; Efremov YM; Ulasov I; Shi B
Adv Mater; 2022 Aug; 34(33):e2203958. PubMed ID: 35738390
[TBL] [Abstract][Full Text] [Related]
19. Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo.
Radin DP; Shifman S; Outhwaite IR; Sharma A; Bases R; Seeliger MA; Tsirka SE
J Pharmacol Exp Ther; 2024 Mar; 389(1):51-60. PubMed ID: 38296645
[TBL] [Abstract][Full Text] [Related]
20. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A
Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
